ストックスクリーナーアプリを入手
24.20
6.56%
1.49
アフターアワーズ：
23.76
-0.44
-1.82%
前日終値:
$22.71
開ける：
$22.89
24時間の取引高:
2.22M
Relative Volume:
0.68
時価総額：
$3.49B
収益：
$62.38M
当期純損益:
$-101.59M
株価収益率:
-28.00
EPS:
-0.8644
ネットキャッシュフロー:
$-139.93M
1週間 パフォーマンス:
-3.74%
1か月 パフォーマンス:
+11.88%
6か月 パフォーマンス:
+222.24%
1年 パフォーマンス:
+1,604%
1日の値動き範囲:
$22.36
$24.25
1週間の範囲:
$20.76
$25.06
52週間の値動き範囲:
$1.03
$28.41
Tango Therapeutics Inc Stock (TNGX) Company Profile
Compare TNGX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
24.20 | 3.28B | 62.38M | -101.59M | -139.93M | -0.8644 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-02 | 開始されました | Canaccord Genuity | Buy |
| 2026-02-23 | 開始されました | Mizuho | Outperform |
| 2025-11-18 | 開始されました | Wolfe Research | Peer Perform |
| 2025-08-19 | 開始されました | Piper Sandler | Overweight |
| 2024-07-17 | 開始されました | Jefferies | Buy |
| 2024-04-04 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-02-12 | 開始されました | Piper Sandler | Overweight |
| 2023-12-08 | 開始されました | B. Riley Securities | Buy |
| 2022-10-20 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Tango Therapeutics Inc (TNGX) 最新ニュース
Tango Therapeutics president, R&D Adam Crystal sells $573k in shares - Investing.com
Tango Therapeutics (TNGX) R&D president exercises 27K options, sells 27K shares - Stock Titan
Tango Therapeutics (TNGX) CFO receives 40,000 RSUs and 240,000 options - Stock Titan
Tango Therapeutics (TNGX) price target increased by 11.68% to 24.38 - MSN
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Invus and Avicenna disclose passive stakes in Tango Therapeutics (NASDAQ: TNGX) - Stock Titan
Jefferies raises Tango Therapeutics stock price target on RAS deal - Investing.com
Stifel reiterates Tango Therapeutics stock Buy rating at $15 - Investing.com
Tango Therapeutics (TNGX) price target increased by 32.09% to 20.06 - MSN
Tango Therapeutics (TNGX) director receives RSU and option grants as board compensation - Stock Titan
Tango Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
TNGX (NASDAQ: TNGX) affiliate files to sell 65,460 shares after option exercise - Stock Titan
New CFO and hire get 512,900 Tango stock awards under Nasdaq rule - Stock Titan
Here's Why We're Not Too Worried About Tango Therapeutics' (NASDAQ:TNGX) Cash Burn Situation - Moomoo
The Nasdaq Biotechnology Index closed down more than 1.2%. Among its constituent stocks, Tango Therapeutics fell by 12.25%, Personalis dropped 8.36%, PTC Therapeutics decreased by 8.13%, Foghorn slid 8.12%, and Erasca declined 7.98%. - Bitget
Tango Therapeutics (NASDAQ:TNGX) Trading Down 9.7%Here's What Happened - MarketBeat
Tango Therapeutics is the best performing healthcare stock in March - MSN
How New C-Suite Hires At Tango Therapeutics (TNGX) Have Changed Its Investment Story - simplywall.st
Stifel raises Tango Therapeutics stock price target on drug combo potential - Investing.com UK
Stifel raises Tango Therapeutics stock price target on drug combo potential By Investing.com - Investing.com South Africa
Stifel Nicolaus Issues Positive Forecast for Tango Therapeutics (NASDAQ:TNGX) Stock Price - MarketBeat
Does Tango Therapeutics (TNGX) Have the Potential to Rally 75.89% as Wall Street Analysts Expect? - MSN
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
[Form 3] Tango Therapeutics, Inc. Initial Statement of Beneficial Ownership - Stock Titan
CFO Matthew Gall (TNGX) files Form 3 with no reported trades - Stock Titan
TNGX Financials: Income Statement, Balance Sheet & Cash Flow | Tango Therapeutics Inc - Stock Titan
Tango Therapeutics stock hits all-time high at 27.16 USD By Investing.com - Investing.com Australia
Tango Therapeutics stock hits all-time high at 27.16 USD - Investing.com
354,192 Shares in Tango Therapeutics, Inc. $TNGX Bought by Mass General Brigham Inc - MarketBeat
Stifel reiterates Tango Therapeutics stock rating on combo potential By Investing.com - Investing.com Australia
Stifel reiterates Tango Therapeutics stock rating on combo potential - Investing.com
HBS1L degradation inducers named in Tango Therapeutics patent - BioWorld News
Is Tango Therapeutics’ New Leadership Bench Reframing Its R&D Ambitions or Its Risk Profile (TNGX)? - simplywall.st
Tango Therapeutics (TNGX) Stock Stop Loss (Eye on Rally) 2026-04-18Stock Ideas - UBND thành phố Hải Phòng
Tango Therapeutics Inc (TNGX) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):